ClinicalTrials.Veeva

Menu

Sensing Contact Lens-based Device for 24-hour Monitoring of Intraocular Pressure

S

Sensimed

Status

Completed

Conditions

Healthy
Glaucoma, Open-Angle

Treatments

Device: Goldfish
Device: Tonometry

Study type

Interventional

Funder types

Industry

Identifiers

NCT03689088
GF-1703

Details and patient eligibility

About

Glaucoma is characterized by irreversible vision loss through the progressive death of optic nerve fibers unless timely diagnosis and adequate treatment are provided. Medical therapy is aimed at lowering intraocular pressure (IOP) below a clinically determined target level in order to prevent or slow glaucoma progression. IOP is known to vary with the time of day as well as with daily activities.

The current way of assessing nycthemeral IOP fluctuation is to perform repeated discrete tonometry measurements, allowing only snapshot and non-continuous measurements once per hour in the best cases. The procedure is cumbersome, expensive, inconvenient (disturbed sleep cycle as patient is awoken for nocturnal/sleep period measurements) and may not detect crucial IOP values in time.

Sensimed AG has developed a new contact lens (CL)-based device intended to continuously measure IOP over 24 hours. The objective of this study is to investigate the use of device for 24-hour IOP monitoring in healthy subjects and glaucoma patients.

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • For Open Angle Glaucoma (OAG) subjects, a clinical diagnosis of primary OAG, including normal tension glaucoma (NTG) all known untreated IOP measurements < 22 mmHg using Goldmann Applanation Tonometry (GAT) for NTG no IOP-lowering treatment; otherwise, a 4-week wash-out period prior to the recording
  • For healthy subjects, no structural defects, normal visual fields, IOP ≤ 21 mmHg and open angles on gonioscopy
  • Aged ≥ 18 years, either gender
  • Body Mass Index ≤ 30 kg/m2
  • Central Corneal Radius (flat meridian) between 7.5 mm (45 D) and 7.9 mm (42.75 D)
  • Central Corneal Thickness between 500 microns and 600 microns
  • Difference in IOP absolute value between eyes within 2.5 mmHg at screening in sitting position
  • Same direction of IOP variation (positive or negative) for the 2 eyes when moving from sitting to supine positions at screening
  • Spherical refraction within ±6.00 diopters and cylinder refraction within ±3.00 diopters
  • Having given written informed consent, prior to any investigational procedures

Exclusion criteria

  • Ocular pathology (other than glaucoma for glaucoma subjects)
  • Previous glaucoma, cataract or refractive surgery
  • Corneal or conjunctival abnormality, precluding contact lens adaptation
  • Severe dry eye syndrome
  • Subjects with allergy to corneal anesthetic
  • Subjects with contraindications for silicone CL wear
  • Subjects with contraindications for Water Drinking Test (WDT) (eg., heart, renal problems)
  • Subjects unable or unwilling to comply with the study procedures
  • Participation in other interventional clinical research within the last 4 weeks

Trial design

Primary purpose

Device Feasibility

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

9 participants in 2 patient groups

Investigational device (Goldfish)
Experimental group
Description:
IOP will be monitored for 24 h in the Goldfish eye
Treatment:
Device: Goldfish
Tonometry
Active Comparator group
Description:
IOP will be acquired by standard tonometry at specific times in the the fellow eye
Treatment:
Device: Tonometry

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems